Thomas Hutson, DO, discusses the final prespecified overall survival analysis of the phase 3 CLEAR study in patients with advanced renal cell carcinoma.
Thomas E. Hutson, DO
Advertisement
Articles by Thomas E. Hutson, DO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
Multidisciplinary Breast Cancer Experts Outline Proactive Strategies for Managing Treatment-Related Toxicities: With Neil Iyengar, MD; Heather Moore, CPP, PharmD; and Sarah Donahue, MPH, NP
4
Dr Neff on the Accuracy and Feasibility of Self-Collected HPV Testing in Cervical Cancer
5